Industry reporting indicates the U.S. Food and Drug Administration is on track to approve the fewest new molecular entities since 2022, leaving more than a dozen companies waiting on regulatory decisions. The slowdown reflects tighter review dynamics and could compress sponsor timelines for launch and market access. Companies with late‑stage assets face extended commercial uncertainty, and investors are recalibrating valuations in light of a more conservative approval environment.